|
Gene: NRIP1 |
Gene summary for NRIP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | NRIP1 | Gene ID | 8204 |
Gene name | nuclear receptor interacting protein 1 | |
Gene Alias | CAKUT3 | |
Cytomap | 21q11.2-q21.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A8K171 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8204 | NRIP1 | HCC2_Meng | Human | Liver | HCC | 9.73e-22 | 1.73e-01 | 0.0107 |
8204 | NRIP1 | HCC2 | Human | Liver | HCC | 5.12e-23 | 5.12e+00 | 0.5341 |
8204 | NRIP1 | Pt13.b | Human | Liver | HCC | 7.56e-04 | 1.25e-02 | 0.0251 |
8204 | NRIP1 | S027 | Human | Liver | HCC | 9.76e-10 | 1.02e+00 | 0.2446 |
8204 | NRIP1 | S028 | Human | Liver | HCC | 1.06e-18 | 1.12e+00 | 0.2503 |
8204 | NRIP1 | S029 | Human | Liver | HCC | 7.45e-15 | 8.56e-01 | 0.2581 |
8204 | NRIP1 | RNA-P17T-P17T-4 | Human | Lung | IAC | 8.82e-04 | 3.86e-01 | 0.343 |
8204 | NRIP1 | RNA-P17T-P17T-6 | Human | Lung | IAC | 3.97e-02 | 3.65e-01 | 0.3385 |
8204 | NRIP1 | RNA-P17T-P17T-8 | Human | Lung | IAC | 4.54e-04 | 5.23e-01 | 0.3329 |
8204 | NRIP1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.01e-06 | 3.33e-01 | -0.2116 |
8204 | NRIP1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.53e-02 | 4.52e-01 | -0.1941 |
8204 | NRIP1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 1.64e-03 | 4.55e-01 | -0.2107 |
8204 | NRIP1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 1.23e-03 | 2.98e-01 | -0.2119 |
8204 | NRIP1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 7.06e-03 | 1.71e-01 | -0.0166 |
8204 | NRIP1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.05e-02 | 1.18e-01 | -0.0132 |
8204 | NRIP1 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.37e-06 | 2.08e-01 | -0.013 |
8204 | NRIP1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.38e-02 | 4.22e-01 | -0.0961 |
8204 | NRIP1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 2.39e-05 | 5.54e-01 | -0.0876 |
8204 | NRIP1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 2.49e-02 | 4.80e-01 | -0.0822 |
8204 | NRIP1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 4.82e-05 | 4.24e-01 | -0.0809 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004860812 | Breast | IDC | reproductive structure development | 60/1434 | 424/18723 | 2.71e-06 | 1.03e-04 | 60 |
GO:006145813 | Breast | IDC | reproductive system development | 60/1434 | 427/18723 | 3.41e-06 | 1.24e-04 | 60 |
GO:003235512 | Breast | IDC | response to estradiol | 27/1434 | 141/18723 | 7.87e-06 | 2.35e-04 | 27 |
GO:005123513 | Breast | IDC | maintenance of location | 48/1434 | 327/18723 | 9.90e-06 | 2.77e-04 | 48 |
GO:0008406 | Breast | IDC | gonad development | 32/1434 | 221/18723 | 3.64e-04 | 5.23e-03 | 32 |
GO:0045137 | Breast | IDC | development of primary sexual characteristics | 32/1434 | 227/18723 | 5.85e-04 | 7.44e-03 | 32 |
GO:00485117 | Breast | IDC | rhythmic process | 38/1434 | 298/18723 | 1.34e-03 | 1.39e-02 | 38 |
GO:0007548 | Breast | IDC | sex differentiation | 35/1434 | 276/18723 | 2.23e-03 | 2.07e-02 | 35 |
GO:004860821 | Breast | DCIS | reproductive structure development | 57/1390 | 424/18723 | 9.06e-06 | 2.45e-04 | 57 |
GO:005123523 | Breast | DCIS | maintenance of location | 47/1390 | 327/18723 | 9.55e-06 | 2.56e-04 | 47 |
GO:006145822 | Breast | DCIS | reproductive system development | 57/1390 | 427/18723 | 1.12e-05 | 2.92e-04 | 57 |
GO:003235521 | Breast | DCIS | response to estradiol | 26/1390 | 141/18723 | 1.34e-05 | 3.33e-04 | 26 |
GO:004851113 | Breast | DCIS | rhythmic process | 37/1390 | 298/18723 | 1.44e-03 | 1.47e-02 | 37 |
GO:00084061 | Breast | DCIS | gonad development | 29/1390 | 221/18723 | 1.96e-03 | 1.84e-02 | 29 |
GO:00451371 | Breast | DCIS | development of primary sexual characteristics | 29/1390 | 227/18723 | 2.93e-03 | 2.52e-02 | 29 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:00076238 | Cervix | CC | circadian rhythm | 46/2311 | 210/18723 | 6.76e-05 | 9.60e-04 | 46 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NRIP1 | SNV | Missense_Mutation | c.459C>G | p.Ile153Met | p.I153M | P48552 | protein_coding | deleterious(0.01) | possibly_damaging(0.906) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NRIP1 | SNV | Missense_Mutation | c.430N>G | p.Leu144Val | p.L144V | P48552 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
NRIP1 | SNV | Missense_Mutation | novel | c.3365N>C | p.Arg1122Thr | p.R1122T | P48552 | protein_coding | deleterious(0.01) | possibly_damaging(0.73) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
NRIP1 | SNV | Missense_Mutation | c.2275N>T | p.Pro759Ser | p.P759S | P48552 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
NRIP1 | SNV | Missense_Mutation | c.997T>C | p.Ser333Pro | p.S333P | P48552 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
NRIP1 | SNV | Missense_Mutation | c.3328N>T | p.Pro1110Ser | p.P1110S | P48552 | protein_coding | tolerated(0.3) | benign(0.009) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NRIP1 | SNV | Missense_Mutation | novel | c.61N>A | p.Leu21Ile | p.L21I | P48552 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NRIP1 | SNV | Missense_Mutation | c.2875G>A | p.Asp959Asn | p.D959N | P48552 | protein_coding | tolerated(0.28) | benign(0.005) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
NRIP1 | deletion | Frame_Shift_Del | novel | c.2429delA | p.Asp810ValfsTer10 | p.D810Vfs*10 | P48552 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
NRIP1 | insertion | Frame_Shift_Ins | novel | c.2427_2428insTTTGGTAAGTGGCCCT | p.Asp810PhefsTer6 | p.D810Ffs*6 | P48552 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8204 | NRIP1 | NUCLEAR HORMONE RECEPTOR | RETINOIC ACID | 15632153,14581481 | ||
8204 | NRIP1 | NUCLEAR HORMONE RECEPTOR | RETINOIDS | 15180561 |
Page: 1 |